应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BDX 碧迪医疗
未开盘 11-21 16:00:00 EST
225.45
+3.06
+1.38%
盘后
225.45
+0.00
0.00%
19:09 EST
最高
225.80
最低
221.03
成交量
161.88万
今开
222.05
昨收
222.39
日振幅
2.14%
总市值
651.65亿
流通市值
650.18亿
总股本
2.89亿
成交额
3.62亿
换手率
0.56%
流通股本
2.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
碧迪医疗2024财年实现净利润17.26亿美元,同比增加12.81%
市场透视 · 11-17
碧迪医疗2024财年实现净利润17.26亿美元,同比增加12.81%
异动解读 | 碧迪医疗盘中大跌逾5% 成长性受质疑
异动解读 · 11-08
异动解读 | 碧迪医疗盘中大跌逾5% 成长性受质疑
碧迪医疗盘中异动 快速下跌5.01%报228.04美元
市场透视 · 11-08
碧迪医疗盘中异动 快速下跌5.01%报228.04美元
BUZZ-第四季度业绩超预期,百通迪金森攀升
路透中文 · 11-07
BUZZ-第四季度业绩超预期,百通迪金森攀升
由于给药设备的强劲表现,Becton Dickinson 季度业绩超出预期
Reuters · 11-07
由于给药设备的强劲表现,Becton Dickinson 季度业绩超出预期
天助畅运IPO中止:国产第一,年收入仅2.2亿元,深交所三问业绩成长性
时代周报-时代在线 · 11-07
天助畅运IPO中止:国产第一,年收入仅2.2亿元,深交所三问业绩成长性
碧迪医疗雒剑:今年有一个战略性项目要落地河南
大河财立方 · 09-26
碧迪医疗雒剑:今年有一个战略性项目要落地河南
碧迪医疗2024财年第二财季实现净利润4.87亿美元,同比增加19.66%
自选股智能写手 · 08-10
碧迪医疗2024财年第二财季实现净利润4.87亿美元,同比增加19.66%
Becton Dickinson and Co 公布截至一月的季度业绩 - 收益摘要
Reuters · 08-01
Becton Dickinson and Co 公布截至一月的季度业绩 - 收益摘要
异动解读 | 碧迪医疗第三季度收入不佳 下调全年利润预期 股价大跌5%
异动解读 · 08-01
异动解读 | 碧迪医疗第三季度收入不佳 下调全年利润预期 股价大跌5%
碧迪医疗盘中异动 早盘大幅下跌5.47%报227.89美元
自选股智能写手 · 08-01
碧迪医疗盘中异动 早盘大幅下跌5.47%报227.89美元
BUZZ-拜顿因第三季度收入不及预期而下跌
Reuters · 08-01
BUZZ-拜顿因第三季度收入不及预期而下跌
药物输送设备需求旺盛,百通迪金森利润超预期
Reuters · 08-01
药物输送设备需求旺盛,百通迪金森利润超预期
Becton Dickinson and Co 预计每股收益3.31美元 - 财报前瞻
Reuters · 07-31
Becton Dickinson and Co 预计每股收益3.31美元 - 财报前瞻
BUZZ-爱德华生命科学公司第二季度营收不及预期,业绩下滑
Reuters · 07-25
BUZZ-爱德华生命科学公司第二季度营收不及预期,业绩下滑
由于心脏设备需求疲软,Edwards Lifesciences 第二季度营收不及预期
Reuters · 07-25
由于心脏设备需求疲软,Edwards Lifesciences 第二季度营收不及预期
花旗:维持Becton Dickinson(BDX.US)评级,由中性调整至中性评级, 目标价由260.00美元调整至255.
智通财经 · 07-11
花旗:维持Becton Dickinson(BDX.US)评级,由中性调整至中性评级, 目标价由260.00美元调整至255.
美国食品和药物管理局示意百通狄金森公司血液试管短缺
Reuters · 07-11
美国食品和药物管理局示意百通狄金森公司血液试管短缺
碧迪医疗举债232亿元加码重症监护,能否扭转业绩下滑颓势?
21世纪经济报道 · 06-07
碧迪医疗举债232亿元加码重症监护,能否扭转业绩下滑颓势?
爱德华生命科学作价42亿美元向碧迪医疗出售重症监护业务
界面 · 06-05
爱德华生命科学作价42亿美元向碧迪医疗出售重症监护业务
加载更多
公司概况
公司名称:
碧迪医疗
所属市场:
NYSE
上市日期:
--
主营业务:
碧迪医疗器械有限公司于1906年11月根据新泽西州法律注册成立。该公司是一家全球性的医疗技术公司,从事医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众使用的各种医疗用品、设备、实验室设备和诊断产品的开发、制造和销售。公司提供客户解决方案,重点是改善药物管理和患者安全;支持感染预防实践;配备手术和介入手术;改进药物输送;协助麻醉护理;加强传染病和癌症的诊断;促进细胞研究和应用;支持糖尿病的管理。
发行价格:
--
{"stockData":{"symbol":"BDX","market":"US","secType":"STK","nameCN":"碧迪医疗","latestPrice":225.45,"timestamp":1732222800000,"preClose":222.39,"halted":0,"volume":1618785,"hourTrading":{"tag":"盘后","latestPrice":225.45,"preClose":225.45,"latestTime":"19:09 EST","volume":52181,"amount":11764214.755,"timestamp":1732234195331},"delay":0,"floatShares":288392621,"shares":289042418,"eps":4.844599,"marketStatus":"未开盘","marketStatusCode":0,"change":3.06,"latestTime":"11-21 16:00:00 EST","open":222.05,"high":225.8,"low":221.03,"amount":362445330.17385,"amplitude":0.021449,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.844599,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732266000000},"adr":0,"listingDate":-240782400000,"adjPreClose":222.39,"adrRate":0,"dividendRate":0.016678,"preHourTrading":{"tag":"盘前","latestPrice":222.94,"preClose":222.39,"latestTime":"09:29 EST","volume":65,"amount":14503.5696,"timestamp":1732199390368},"postHourTrading":{"tag":"盘后","latestPrice":225.45,"preClose":225.45,"latestTime":"19:09 EST","volume":52181,"amount":11764214.755,"timestamp":1732234195331},"volumeRatio":0.908769,"impliedVol":0.1782,"impliedVolPercentile":0.0714},"requestUrl":"/m/hq/s/BDX","defaultTab":"news","newsList":[{"id":"2484615543","title":"碧迪医疗2024财年实现净利润17.26亿美元,同比增加12.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484615543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484615543?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:00","pubTimestamp":1731772816,"startTime":"0","endTime":"0","summary":"11月17日,碧迪医疗公布财报,公告显示公司2024财年净利润为17.26亿美元,同比增加12.81%;其中营业收入为201.78亿美元,同比增加4.16%,每股基本收益为5.96美元。从资产负债表来看,碧迪医疗总负债313.75亿美元,其中短期债务21.70亿美元,资产负债比为1.83,流动比率为1.18。机构评级:截至2024年11月17日,当前有13家机构对碧迪医疗目标价做出预测,其中目标均价为276.54美元,其中最低目标价为250.00美元,最高目标价为312.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000030abc78e0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000030abc78e0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BDX"],"gpt_icon":0},{"id":"1112915756","title":"异动解读 | 碧迪医疗盘中大跌逾5% 成长性受质疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1112915756","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112915756?lang=zh_cn&edition=full","pubTime":"2024-11-08 03:14","pubTimestamp":1731006896,"startTime":"0","endTime":"0","summary":"11月7日,碧迪医疗股价盘中大跌逾5%,引发市场广泛关注。数据显示,碧迪医疗第四季度业绩超预期,但公司业绩增长可持续性遭到质疑。而在这一细分市场,外资厂商如强生、美敦力等占据主导地位,碧迪医疗国内市场份额仅为11.29%,排名第三。另一方面,碧迪医疗的研发投入水平远低于同行业可比公司平均值。虽然公司有多个在研产品线,但这些新产品的市场空间增量有限,对公司整体收入的提振作用受到质疑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 碧迪医疗盘中大跌逾5% 成长性受质疑","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BDX"],"gpt_icon":0},{"id":"2481130027","title":"碧迪医疗盘中异动 快速下跌5.01%报228.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481130027","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481130027?lang=zh_cn&edition=full","pubTime":"2024-11-08 03:12","pubTimestamp":1731006734,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日03时12分,碧迪医疗股票出现波动,股价大幅跳水5.01%。截至发稿,该股报228.04美元/股,成交量186.966万股,换手率0.65%,振幅6.22%。最近的财报数据显示,该股实现营业收入49.90亿美元,净利润4.87亿美元,每股收益1.68美元,毛利23.07亿美元,市盈率47.25倍。碧迪医疗股票所在的医疗设备行业中,整体涨幅为0.19%。碧迪医疗业务占总业务量的近一半,碧迪生命科学业务和 碧迪介入业务占其余部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110803121498e4145e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110803121498e4145e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1854103824.USD","LU1854104046.USD","BK4504","LU0511384066.AUD","BDX","LU1059921491.USD","LU0266013472.USD","LU0289739343.SGD","BK4585","BK4082","LU1571399168.USD","LU0289961442.SGD","IE00BFXG1179.USD","BK4588"],"gpt_icon":0},{"id":"2481902889","title":"BUZZ-第四季度业绩超预期,百通迪金森攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2481902889","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481902889?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:18","pubTimestamp":1730985537,"startTime":"0","endTime":"0","summary":"BUZZ-第四季度业绩超预期,百通迪金森攀升11月7日 - ** 医疗设备制造商Becton Dickinson BDX.N股价盘前上涨2.5%至246美元。** 截至上次收盘,股价累计下跌 1.5(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4T3ME1LJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289961442.SGD","LU1571399168.USD","LU0266013472.USD","LU0289739343.SGD","BK4504","LU0511384066.AUD","BK4588","BK4082","BK4585","LU1059921491.USD","LU1854103824.USD","IE00BFXG1179.USD","LU1854104046.USD","BDX"],"gpt_icon":0},{"id":"2481390608","title":"由于给药设备的强劲表现,Becton Dickinson 季度业绩超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2481390608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481390608?lang=zh_cn&edition=full","pubTime":"2024-11-07 20:40","pubTimestamp":1730983222,"startTime":"0","endTime":"0","summary":"Becton、Boston Scientific 和雅培实验室 等医疗技术公司一直受益于非必要外科手术的强劲需求,特别是老年患者的需求。Becton 生产和销售针头、注射器和处理装置等医疗和外科产品。但该公司提供诊断设备的生命科学部门的销售额却低于预期。Becton 在 9 月份完成了对 Edwards Lifesciences 重症监护产品的收购,其中包括先进的血液和心脏监测系统。Becton 公司第四季度的总营收为 54.4 亿美元,高于分析师预计的 53.8 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","BK4588","LU0289739343.SGD","LU0289961442.SGD","BK4082","LU0511384066.AUD","BK4585","IE00BFXG1179.USD","LU0266013472.USD","LU1571399168.USD","LU1854104046.USD","LU1059921491.USD","LU1854103824.USD","BDX"],"gpt_icon":0},{"id":"2481386976","title":"天助畅运IPO中止:国产第一,年收入仅2.2亿元,深交所三问业绩成长性","url":"https://stock-news.laohu8.com/highlight/detail?id=2481386976","media":"时代周报-时代在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481386976?lang=zh_cn&edition=full","pubTime":"2024-11-07 18:30","pubTimestamp":1730975400,"startTime":"0","endTime":"0","summary":"9月30日,由于财务资料已过有效期,天助畅运IPO审核进入中止状态,这是自去年6月过会以来,天助畅运IPO第三次中止。不过,由于疝修补产品的市场规模较小,2022年天助畅运的营收仅为2.2亿元。因此,深交所在三轮问询中均要求其结合产品市场空间等说明业绩成长性。因此,在三轮问询中,深交所均重点问询了天助畅运业绩的成长性及可持续性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-11-07/doc-incvfuhw9045308.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-11-07/doc-incvfuhw9045308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4566","BDX","IE00BQXX3F31.USD","IE0002270589.USD","LU0211331839.USD","BK4559","BK4568","LU0114720955.EUR","LU0208291251.USD","LU2089284900.SGD","LU0122379950.USD","BK0251","BK4550","LU0211326839.USD","LU0345769631.USD","LU1066051225.USD","IE000M9KFDE8.USD","BK4581","688013","BK4082","LU0203345920.USD","LU0203347892.USD","LU0889566641.SGD","BK4532","LU0640476718.USD","JNJ","IE00B1BXHZ80.USD","IE00BDGV0183.EUR","LU0234572021.USD","LU0795875169.SGD","LU1066051811.HKD","LU2111349929.HKD","LU1221951046.USD","IE00B19Z3581.USD","LU0234570918.USD","BK4585","LU1291159041.SGD","BK4533","IE00BSNM7G36.USD","BK4588","LU1571399168.USD","IE00B19Z3B42.SGD","LU0345770993.USD","301290","LU1074936037.SGD","BK4534","LU1162221912.USD","LU1023059063.AUD","MDT","LU0912757837.SGD"],"gpt_icon":0},{"id":"2470272441","title":"碧迪医疗雒剑:今年有一个战略性项目要落地河南","url":"https://stock-news.laohu8.com/highlight/detail?id=2470272441","media":"大河财立方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470272441?lang=zh_cn&edition=full","pubTime":"2024-09-26 14:26","pubTimestamp":1727331976,"startTime":"0","endTime":"0","summary":"【大河财立方记者王鑫】9月25日,以“投资河南跨享未来”为主题的2024河南与跨国公司合作交流会在郑州隆重举行。当天下午,作为大会系列活动之一,现代医药产业圆桌对接会吸引了众多医疗机构及跨国药企参与,与会者就医药产业相关议题展开讨论。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202409263191970974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4588","LU1854104046.USD","BK4082","LU0511384066.AUD","BDX","LU0289961442.SGD","IE00BFXG1179.USD","LU1059921491.USD","LU1854103824.USD","BK4504","LU0266013472.USD","LU0289739343.SGD","LU1571399168.USD"],"gpt_icon":0},{"id":"2458385516","title":"碧迪医疗2024财年第二财季实现净利润4.87亿美元,同比增加19.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458385516","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458385516?lang=zh_cn&edition=full","pubTime":"2024-08-10 00:15","pubTimestamp":1723220117,"startTime":"0","endTime":"0","summary":"8月10日,碧迪医疗公布财报,公告显示公司2024财年第二财季净利润为4.87亿美元,同比增加19.66%;其中营业收入为49.90亿美元,同比增加2.30%,每股基本收益为1.68美元。从资产负债表来看,碧迪医疗总负债297.14亿美元,其中短期债务11.92亿美元,资产负债比为1.88,流动比率为1.85。机构评级:截至2024年8月10日,当前有14家机构对碧迪医疗目标价做出预测,其中目标均价为275.03美元,其中最低目标价为240.00美元,最高目标价为312.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408100015209f1e0e94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408100015209f1e0e94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BDX"],"gpt_icon":0},{"id":"2456330484","title":"Becton Dickinson and Co 公布截至一月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2456330484","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456330484?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:53","pubTimestamp":1722520413,"startTime":"0","endTime":"0","summary":" * Becton Dickinson and Co 公布的截至1月份的季度调整后每股收益为3.50美元,高于去年同期的每股收益2.96美元。15 位分析师对该季度的平均预期为每股收益 3.31 美元。华尔街预期为每股收益 3.27 美元至 3.37 美元。* 营收为 50.6 亿美元,同比增长 3.7%;分析师预期为 50.8 亿美元。* 据报告,Becton Dickinson 公司本季度每股收益为 1.68 美元。* 公司报告的季度净收入为 4.87 亿美元。* 本季度 Becton Dickinson and Co 的股价上涨了 3.1%,今年到目前为止下跌了 1.1%。华尔街对 Becton Dickinson and Co 的 12 个月目标价中位数为 280.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU1854103824.USD","LU1854104046.USD","BK4082","BDX","IE00BFXG1179.USD","LU1571399168.USD","LU0289739343.SGD","LU0289961442.SGD","BK4588","BDXA","BK4585","LU0511384066.AUD","BK4504"],"gpt_icon":0},{"id":"1109586954","title":"异动解读 | 碧迪医疗第三季度收入不佳 下调全年利润预期 股价大跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109586954","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109586954?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:38","pubTimestamp":1722519539,"startTime":"0","endTime":"0","summary":"医疗设备制造商碧迪医疗(BDX)周四盘中股价大跌5.03%,引发市场广泛关注。这主要是由于公司公布的第三季度财报数据不佳所致。\n\n碧迪医疗公布,第三季度营收为50.8亿美元,低于分析师平均预期。尽管公司每股收益3.50美元高于预期,但营收不佳仍令投资者失望。\n\n与此同时,碧迪医疗还下调了全年利润预期的下限,将其从每股12.95美元上调至13.05美元,上限13.15美元不变。这一调整也加剧了市场对公司前景的担忧,导致股价大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX"],"gpt_icon":0},{"id":"2456438992","title":"碧迪医疗盘中异动 早盘大幅下跌5.47%报227.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456438992","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456438992?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:31","pubTimestamp":1722519096,"startTime":"0","endTime":"0","summary":"北京时间2024年08月01日21时31分,碧迪医疗股票出现波动,股价大幅下跌5.47%。截至发稿,该股报227.89美元/股,成交量8.2408万股,换手率0.03%,振幅1.08%。碧迪医疗股票所在的医疗设备行业中,整体跌幅为0.48%。碧迪医疗公司简介:碧迪医疗是全球最大的医疗手术产品制造商和分销商。碧迪医疗业务占总业务量的近一半,碧迪生命科学业务和 碧迪介入业务占其余部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408012131379f05afbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408012131379f05afbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0511384066.AUD","BK4504","LU1571399168.USD","IE00BFXG1179.USD","BDX","LU0289961442.SGD","BK4588","LU1854103824.USD","BK4585","BK4082","LU0289739343.SGD","LU0266013472.USD","LU1854104046.USD"],"gpt_icon":0},{"id":"2456871574","title":"BUZZ-拜顿因第三季度收入不及预期而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2456871574","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456871574?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:11","pubTimestamp":1722517876,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 8月1日 - ** 医疗设备制造商 Becton Dickinson 股价盘前下跌 5.2% 至 228.61 美元** (link),低于分析师平均预期的 50.8 亿美元。** 每股收益 3.50 美元,低于分析师平均预期的每股收益 3.31 美元 - LSEG 数据** 公司将全年副利润预测区间的下限从每股12.95美元上调至13.05美元,将上限维持在13.15美元不变。** 截至上次收盘,股价累计下跌 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BDX","BUZZ","BK4082","LU1854104046.USD","LU0266013472.USD","LU0289961442.SGD","LU0511384066.AUD","LU0289739343.SGD","IE00BFXG1179.USD","LU1571399168.USD","LU1854103824.USD","BK4504"],"gpt_icon":0},{"id":"2456489029","title":"药物输送设备需求旺盛,百通迪金森利润超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2456489029","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456489029?lang=zh_cn&edition=full","pubTime":"2024-08-01 20:24","pubTimestamp":1722515074,"startTime":"0","endTime":"0","summary":" 路透8月1日 - 拜克顿-迪金森公司 周四公布的第三季度 利润好于预期,这得益于对其给药设备的强劲需求。这家设备制造商曾表示,预计这项交易将立即增加其所有关键财务指标。这家总部位于新泽西州的集团将全年调整后利润预测区间的下限从 12.95 美元上调至 13.05 美元,上限维持在 13.15 美元不变。截至 6 月 30 日的第三季度,该公司调整后每股收益为 3.50 美元,高于分析师预计的每股 3.31 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0950375773.USD","LU2324357040.USD","LU1989764748.USD","LU1430594728.SGD","LU1989771016.USD","LU2506951958.HKD","BK4585","LU1066051811.HKD","LU0912757837.SGD","ABT","BK4082","LU1032466523.USD","LU1280957306.USD","LU1989763427.SGD","SG9999002232.USD","BK4581","BK4566","LU1585245621.USD","LU1854104046.USD","BSX","LU2362541273.HKD","BK4550","LU0170899867.USD","LU1291159041.SGD","LU1989764664.SGD","BK4007","IE00BJT1NW94.SGD","LU1057294990.SGD","BDX","LU0238689110.USD","LU1989772840.SGD","LU2491049909.HKD","LU0466842654.USD","LU1732799900.SGD","LU1935042991.SGD","BK4588","LU1061106388.HKD","BK4504","IE00BSNM7G36.USD","LU1066053197.SGD","LU1732800096.USD","LU1023059063.AUD","LU2087625088.SGD","SG9999002224.SGD","LU2491050154.USD","LU0823416689.USD","LU0795875086.SGD","LU2491050071.SGD","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2455961027","title":"Becton Dickinson and Co 预计每股收益3.31美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455961027","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455961027?lang=zh_cn&edition=full","pubTime":"2024-07-31 02:36","pubTimestamp":1722364590,"startTime":"0","endTime":"0","summary":" * Becton Dickinson and Co 预计将在8月1日公布截至2024年6月30日的季度收入报告。* 根据LSEG的数据,13位分析师的平均预期显示,这家总部位于新泽西富兰克林湖区的公司的营收预计将从去年同期的48.8亿美元增长4.1%,达到50.76亿美元。 * LSEG 的分析师平均预期 Becton Dickinson and Co 每股收益为 3.31 美元。* 华尔街对 Becton Dickinson and Co 的 12 个月目标价中位数为 280.00 美元,高于其上次收盘价 237.84 美元。7月30日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX","BDXA"],"gpt_icon":0},{"id":"2454851670","title":"BUZZ-爱德华生命科学公司第二季度营收不及预期,业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2454851670","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454851670?lang=zh_cn&edition=full","pubTime":"2024-07-25 05:54","pubTimestamp":1721858043,"startTime":"0","endTime":"0","summary":" 7月24日 - ** 医疗设备制造商爱德华生命科学公司股价在盘后交易中下跌超过16%,至72.7美元。** 受人工心脏瓣膜需求低于预期的影响,该公司第二季度营收不及预期** 营收为13.9亿美元,低于分析师预计的16.5亿美元--LSEG数据;每股收益为70美分,略高于预计的69美分。** EW 预测第三季度销售额在 15.6 亿美元至 16.4 亿美元之间,假定整个季度都包括其重症监护部门的收入,该部门已同意以 42 亿美元的价格出售给 Becton Dickinson 公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX","BUZZ","EW"],"gpt_icon":0},{"id":"2454515618","title":"由于心脏设备需求疲软,Edwards Lifesciences 第二季度营收不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2454515618","media":"Reuters","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454515618?lang=zh_cn&edition=full","pubTime":"2024-07-25 05:49","pubTimestamp":1721857785,"startTime":"0","endTime":"0","summary":"LSEG数据显示,爱德华兹公司第二季度营收为13.9亿美元,低于分析师预计 的16.5亿美元。另外,爱德华兹公司上个月将 ,将其重症监护产品部门 出售 给了Becton Dickinson ,该公司表示将收购心脏设备制造商JenaValve Technology和Endotronix,以扩大其结构性心脏产品组合 。这些交易的价值约为12亿美元,进一步巩固了Edwards向纯粹的结构性心脏公司的转型,其主导产品是经导管主动脉瓣置换 设备,用于微创心脏手术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDT","ABT","BDX","EW"],"gpt_icon":0},{"id":"2450187576","title":"花旗:维持Becton Dickinson(BDX.US)评级,由中性调整至中性评级, 目标价由260.00美元调整至255.","url":"https://stock-news.laohu8.com/highlight/detail?id=2450187576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450187576?lang=zh_cn&edition=full","pubTime":"2024-07-11 09:00","pubTimestamp":1720659639,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LU0310800965.SGD","LU1162221912.USD","LU0648001328.SGD","LU2456880835.USD","BK4207","LU0130517989.USD","LU1571399168.USD","IE00BSNM7G36.USD","BK4588","LU2417539215.USD","LU0511384066.AUD","BK4534","BK4566","LU0106831901.USD","LU1201861249.SGD","LU0162691827.USD","LU1267930227.SGD","LU0980610538.SGD","LU0320765646.SGD","LU1854104046.USD","BK4082","LU0477156953.USD","LU1668664300.SGD","IE00BFXG1179.USD","LU0072461881.USD","LU0052756011.USD","LU0128525689.USD","LU0266013472.USD","LU1366192091.USD","LU0289739343.SGD","LU2236285917.USD","LU0098860793.USD","LU1791807156.HKD","BDX","LU0289961442.SGD","LU0130102774.USD","LU2462157665.USD","LU1854103824.USD","BK4504"],"gpt_icon":0},{"id":"2450848267","title":"美国食品和药物管理局示意百通狄金森公司血液试管短缺","url":"https://stock-news.laohu8.com/highlight/detail?id=2450848267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450848267?lang=zh_cn&edition=full","pubTime":"2024-07-11 00:49","pubTimestamp":1720630166,"startTime":"0","endTime":"0","summary":" 路透7月10日 - 美国食品和药物管理局周三向实验室和医疗服务提供商发出警告,称用于诊断细菌和真菌感染的Becton Dickinson 血液试管出现短缺。背景上个月,Becton 公司向 发函警告,由于供应商塑料瓶供应量减少,未来几个月 BACTEC 血液培养基供应可能会出现延误。Becton 公司表示正在采取措施解决这一问题,包括使用空运和修改生产计划以实现快速生产。数字美国疾病控制与预防中心称,美国每年至少有 170 万成年人患败血症,近 27 万人因此死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU0289739343.SGD","BDX","BK4585","LU1854103824.USD","LU1854104046.USD","BK4588","LU1571399168.USD","IE00BFXG1179.USD","LU0511384066.AUD","LU0266013472.USD","LU0289961442.SGD","BK4082"],"gpt_icon":0},{"id":"2441051879","title":"碧迪医疗举债232亿元加码重症监护,能否扭转业绩下滑颓势?","url":"https://stock-news.laohu8.com/highlight/detail?id=2441051879","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441051879?lang=zh_cn&edition=full","pubTime":"2024-06-07 18:52","pubTimestamp":1717757573,"startTime":"0","endTime":"0","summary":"为了筹集收购资金,碧迪医疗计划动用约10亿美元的现金,以及32亿美元的新债务,这一债务折合人民币约232亿元。碧迪医疗举债收购的首要原因或许为业绩压力,其净利润在近两年半内连续下滑。期间碧迪医疗实现净利润14.84亿美元,同比下降16.6%;2022年实现净利润17.79亿美元,同比下降14.96%。本次集采中,碧迪医疗的留置针中标价格包括4.8元、4.2元、13.99元等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406071856149f241618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406071856149f241618&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","BK4504","LU0266013472.USD","BK4585","BK4588","LU1854103824.USD","LU0511384066.AUD","LU1854104046.USD","LU0289739343.SGD","BDX","LU1571399168.USD","LU0289961442.SGD"],"gpt_icon":0},{"id":"2441264367","title":"爱德华生命科学作价42亿美元向碧迪医疗出售重症监护业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2441264367","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441264367?lang=zh_cn&edition=full","pubTime":"2024-06-05 06:57","pubTimestamp":1717541832,"startTime":"0","endTime":"0","summary":"爱德华生命科学(Edwards Lifesciences)近日宣布与碧迪医疗(Becton, Dickinson and Company)达成最终协议,将旗下重症监护全线产品以42亿美元现金方式出售给碧迪医疗。基于此项协议,爱德华不再继续推进此前宣布的重症监护业务分拆计划。该交易预计将在2024年底前完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605065712af8bf51f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605065712af8bf51f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BDX","BK4082","LU0266013472.USD","LU0289961442.SGD","LU1571399168.USD","BK4504","LU0289739343.SGD","LU0511384066.AUD","LU1854104046.USD","LU1854103824.USD","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bd.com","stockEarnings":[{"period":"1week","weight":-0.0076},{"period":"1month","weight":-0.0595},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0146},{"period":"1year","weight":-0.0479},{"period":"ytd","weight":-0.0754}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"碧迪医疗器械有限公司于1906年11月根据新泽西州法律注册成立。该公司是一家全球性的医疗技术公司,从事医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众使用的各种医疗用品、设备、实验室设备和诊断产品的开发、制造和销售。公司提供客户解决方案,重点是改善药物管理和患者安全;支持感染预防实践;配备手术和介入手术;改进药物输送;协助麻醉护理;加强传染病和癌症的诊断;促进细胞研究和应用;支持糖尿病的管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.038615},{"month":2,"riseRate":0.5,"avgChangeRate":0.004773},{"month":3,"riseRate":0.568182,"avgChangeRate":-0.003408},{"month":4,"riseRate":0.511111,"avgChangeRate":0.007201},{"month":5,"riseRate":0.488889,"avgChangeRate":0.013555},{"month":6,"riseRate":0.622222,"avgChangeRate":0.006927},{"month":7,"riseRate":0.577778,"avgChangeRate":-0.000947},{"month":8,"riseRate":0.644444,"avgChangeRate":0.00845},{"month":9,"riseRate":0.377778,"avgChangeRate":-0.001917},{"month":10,"riseRate":0.488889,"avgChangeRate":0.006834},{"month":11,"riseRate":0.644444,"avgChangeRate":0.02107},{"month":12,"riseRate":0.681818,"avgChangeRate":0.02022}],"exchange":"NYSE","name":"碧迪医疗","nameEN":"Becton Dickinson"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"碧迪医疗(BDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供碧迪医疗(BDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"碧迪医疗,BDX,碧迪医疗股票,碧迪医疗股票老虎,碧迪医疗股票老虎国际,碧迪医疗行情,碧迪医疗股票行情,碧迪医疗股价,碧迪医疗股市,碧迪医疗股票价格,碧迪医疗股票交易,碧迪医疗股票购买,碧迪医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"碧迪医疗(BDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供碧迪医疗(BDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}